A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Active:	Yes
Cancer Type:	Head and Neck Cancer Unknown Primary	NCT ID:	NCT06256588
Trial Phases:	Phase III	Protocol IDs:	221530 (primary) NCI-2024-04986 2023-508613-17 2023-508613-17-00
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	GlaxoSmithKline
NCI Full Details:	http://clinicaltrials.gov/show/NCT06256588

Summary

The goal of this study is to assess the safety and effectiveness of Dostarlimab compared
to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.